60 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-ZC-FT-426292 Jun 07, 2019 - Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M http://www.zacks.com/stock/news/427724/merck-mrk-to-buy-private-biotech-tilos-for-up-to-%24773m?cid=CS-ZC-FT-427724 Jun 11, 2019 - Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/428338/mercks-keytruda-wins-fda-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-428338 Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-ZC-FT-429560 Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice http://www.zacks.com/stock/news/432232/are-you-looking-for-a-top-momentum-pick-why-merck-mrk-is-a-great-choice?cid=CS-ZC-FT-432232 Jun 20, 2019 - Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Stock Market News For Jun 20, 2019 http://www.zacks.com/stock/news/432206/stock-market-news-for-jun-20-2019?cid=CS-ZC--432206 Jun 20, 2019 - Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod http://www.zacks.com/stock/news/432688/pharma-stock-roundup-pfe-to-buy-arry-rhhby-mrk-azn-drugs-get-regulatory-nod?cid=CS-ZC-FT-432688 Jun 21, 2019 - Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma http://www.zacks.com/stock/news/432790/dow-30-stock-roundup-boeings-%2465b-air-force-contract-pfizer-to-buy-array-biopharma?cid=CS-ZC-FT-432790 Jun 21, 2019 - The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Kidney-Cancer Market: Good for Patients, Hard for Investors https://www.fool.com/investing/2019/04/23/kidney-cancer-market-good-for-patients-hard-for-in.aspx?source=iedfolrf0000001 Apr 23, 2019 - Drugmakers battle for patients.
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? http://www.zacks.com/stock/news/392203/whats-in-the-cards-for-astrazeneca-azn-in-q1-earnings?cid=CS-ZC-FT-392203 Apr 23, 2019 - AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.

Pages: 123456

<<<Page 3>